Autoinjectors Market Size, Share, Forecast, & Trends Analysis by Type, Technology, Application, Distribution, Route of Administration, End User

Description

List of Tables

Autoinjectors Market Size, Share, Forecast, & Trends Analysis by Type (Disposable, Reusable, Wearable), Technology (Manual, Automatic), Application (Arthritis, Diabetes, Osteoporosis), Distribution, Route of Administration, End User-Global Forecast to 2031

The autoinjectors market is projected to reach $3.76 billion by 2031 at a CAGR of 8.3% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the autoinjectors market is driven by the rising disease burden globally, the preference for self-administration of drugs, and the development of advanced autoinjectors. However, the availability of alternatives to autoinjectors, their high cost, and concerns regarding needlestick injury are restraining the market's growth.

Furthermore, the rising demand for home healthcare and growing partnerships and collaborations by key market players are expected to generate market growth opportunities. However, lack of awareness about the usage of autoinjectors in developing countries and limited access to healthcare in emerging countries are major challenges in the autoinjectors market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the autoinjectors market are Becton, Dickinson and Company (U.S.), Ypsomed AG (Switzerland), SHL Medical (Switzerland), Recipharm AB (Sweden), Owen Mumford Limited (U.K), Halozyme, Inc. (U.S.), AstraZeneca (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Solteam Incorporation Co., Ltd. (China), Gerresheimer AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Bayer AG (Germany), and Union Medico ApS. (Denmark).

Among all the autoinjector types studied in this report, the smart autoinjectors segment is projected to register the highest CAGR of 9.7% during the forecast period. The high CAGR of the segment is attributed to the benefits of smart autoinjectors, technological advancements in smart autoinjectors, and the rise in digitized drug delivery. Digital drug delivery has shown improved patient outcomes in multiple drug treatments. In May 2021, Phillips-Medisize, LLC (U.S.), a company specializing in drug delivery, diagnostic, and MedTech devices, introduced the Aria Smart Autoinjector platform to unlock innovation, differentiation, and sustainability in the digital drug-delivery device market.

Among all the routes of administration studied in this report, in 2024, the subcutaneous segment is expected to account for a larger share of the autoinjectors market. The segment's larger share can be attributed to the rising number of newly launched drugs for subcutaneous self-administration and the higher adoption due to cost-effectiveness.

Among all the technologies studied in this report, in 2024, the manual autoinjector segment is expected to account for the larger share of the autoinjectors market. The larger market share can be attributed to the high adoption of manual autoinjectors due to their lower prices than automatic autoinjectors and easy accessibility in the distribution channel.

Among all the applications studied in this report, in 2024, the diabetes segment is expected to account for the largest share of the autoinjectors market. The segment's larger share can be attributed to the high burden of diabetes globally coupled with patient inclination towards self-administration of insulin. For instance, according to the Centers for Disease Control and Prevention, as of May 2024, around 38.4 million individuals in the U.S. had diabetes (11.6% of the U.S. population).

Among all the distribution channels studied in this report, in 2024, the retail pharmacies segment is expected to account for the largest share of the autoinjectors market. The segment's large market can be attributed to its easy accessibility to autoinjectors in retail pharmacies. Retail pharmacies enable patients to choose between autoinjectors that best suit their needs as per physician recommendations.

Among all the end users studied in this report, the homecare segment is projected to register the highest CAGR of 8.8% during the forecast period. The segment's fast growth can be attributed to patients' growing preference for self-administration. Technological developments in autoinjectors, such as smart autoinjectors available in the audio and visual feedback system, enable enhanced safety for patients in home care, thereby improving patient outcomes.

An in-depth analysis of the geographical scenario of the autoinjectors market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia-Pacific is projected to register the highest CAGR of 8.8% during the forecast period. The fastest growth of the market is due to rising spending on healthcare, advancing healthcare, rising preference for home care, and growing awareness among patients or caretakers regarding self-administration of drugs.

Scope of the Report:

Autoinjectors Market Assessment-by Type

Disposable Autoinjectors
Reusable Autoinjectors
Smart Autoinjectors
- Bluetooth Connectivity
- Near Field Communication (NFC) Connectivity
Wearable Autoinjectors

Autoinjectors Market Assessment-by Route of Administration

Subcutaneous
Intramuscular

Autoinjectors Market Assessment-by Technology

Manual Autoinjectors
Automatic Autoinjectors

Autoinjectors Market Assessment-by End User

Hospitals & Clinics
Ambulatory Surgical Centers

Autoinjectors Market Assessment-by Application

Diabetes
Rheumatoid Arthritis
Osteoporosis
Multiple Sclerosis
Other Applications

(Note: Other applications include epilepsy, oncology, anaphylaxis, migraine, and anemia.)

Autoinjectors Market Assessment-by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online/E-commerce Platforms

Autoinjectors Market Assessment-by End User

Home Care
Hospitals & Clinics
Other End Users

(Note: Other end users include long-term care settings and military & defense)

Autoinjectors Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K
- Italy
- Spain
- Austria
- Netherlands
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Product Code: MRHC - 1041216

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Data Collection & Validation Process
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing & Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. Increasing Prevalence of Chronic & Autoimmune Diseases
- 4.2.2. Growing Demand for Self-administration
- 4.2.3. Technological Advancements in Autoinjectors
4.3. Restraints
- 4.3.1. Availability of Alternatives to Autoinjectors
- 4.3.2. High Costs of Autoinjectors
- 4.3.3. Needlestick Injury Concerns
4.4. Opportunities
- 4.4.1. Growing Demand for Home Healthcare
- 4.4.2. Partnerships & Collaborations by Market Players
4.5. Challenges
- 4.5.1. Limited Access to Healthcare in Developing Countries
- 4.5.2. Lack of Knowledge and Awareness Regarding Autoinjector Usage in Emerging Economies
4.6. Trends
- 4.6.1. Smart/Electronic Autoinjectors
- 4.6.2. Increasing Adoption of Wearable Devices
4.7. Factor Analysis
4.8. Regulatory Analysis
- 4.8.1. U.S.
- 4.8.2. Canada
- 4.8.3. Europe
- 4.8.4. China
- 4.8.5. Japan
- 4.8.6. India
- 4.8.7. Latin America
- 4.8.8. Middle East
4.9. Pricing Analysis
4.10. Parent/Adjacent Market Analysis
4.11. Porter's Five Forces Analysis

5. Autoinjectors Market Assessment-by Type

5.1. Overview
5.2. Disposable Autoinjectors
5.3. Reusable Autoinjectors
5.4. Smart Autoinjectors
- 5.4.1. Bluetooth Connectivity
- 5.4.2. Near Field Communication (NFC) Connectivity
5.5. Wearable Autoinjectors

6. Autoinjectors Market Assessment-by Route of Administration

6.1. Overview
6.2. Subcutaneous
6.3. Intramuscular

7. Autoinjectors Market Assessment-by Technology

7.1. Overview
7.2. Manual
7.3. Automatic

8. Autoinjectors Market Assessment-by Application

8.1. Overview
8.2. Rheumatoid Arthritis
8.3. Osteoporosis
8.4. Diabetes
8.5. Multiple Sclerosis
8.6. Other Applications

9. Autoinjectors Market Assessment-by Distribution Channel

9.1. Overview
9.2. Hospital Pharmacies
9.3. Retail Pharmacies
9.4. Online/E-commerce Platforms

10. Autoinjectors Market Assessment-by End User

10.1. Overview
10.2. Home Care
10.3. Hospitals & Clinics
10.4. Other End Users

11. Autoinjectors Market Assessment-by Geography

11.1. Overview
11.2. North America
- 11.2.1. U.S.
- 11.2.2. Canada
11.3. Europe
- 11.3.1. Germany
- 11.3.2. France
- 11.3.3. U.K.
- 11.3.4. Italy
- 11.3.5. Spain
- 11.3.6. Austria
- 11.3.7. Netherlands
- 11.3.8. Rest of Europe
11.4. Asia-Pacific
- 11.4.1. Japan
- 11.4.2. China
- 11.4.3. India
- 11.4.4. Australia
- 11.4.5. South Korea
- 11.4.6. Rest of Asia-Pacific
11.5. Latin America
- 11.5.1. Brazil
- 11.5.2. Mexico
- 11.5.3. Rest of Latin America
11.6. Middle East & Africa

12. Competition Analysis

12.1. Overview
12.2. Key Growth Strategies
12.3. Competitive Benchmarking
12.4. Competitive Dashboard
- 12.4.1. Industry Leaders
- 12.4.2. Market Differentiators
- 12.4.3. Vanguards
- 12.4.4. Emerging Companies
12.5. Market Share Analysis/Market Rankings of Key Players (2023)

13. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

13.1. Novo Nordisk A/S
13.2. Eli Lilly and Company
13.3. Sanofi S.A.
13.4. Biocon Limited
13.5. Becton, Dickinson and Company
13.6. Ypsomed AG
13.7. Owen Mumford Limited
13.8. Medtronic plc
13.9. Emperra GmbH E-Health Technologies
13.10. pendiq GmbH
13.11. Jiangsu Delfu medical device Co., Ltd

(Note: SWOT analysis will be provided for the top 5 companies.)

14. Appendix

14.1. Available Customization
14.2. Related Reports